Consio | $3,300,000 | (Jan 27, 2026)
Orbital(US) | $60,000,000 | (Jan 27, 2026)
Inferact | $150,000,000 | (Jan 27, 2026)
Certified by Founder
Lodge
Bolden Therapeutics
start up
United States
- Providence, Rhode Island
- 10/01/2024
- Unknown
- Undisclosed Amount
Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.
- Industry Biotechnology Research
- Website https://www.boldentherapeutics.com/
- LinkedIn https://www.linkedin.com/company/bolden-therapeutics/about/
Visitt | $22,000,000 | (Jan 27, 2026)
Cashmere(US) | $5,000,000 | (Jan 27, 2026)
Barnwell Bio | $6,000,000 | (Jan 27, 2026)
Mine(US) | $14,000,000 | (Jan 27, 2026)
Lucend | $3,300,000 | (Jan 27, 2026)
Standard Nuclear | $140,000,000 | (Jan 27, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)